Trial · NCT04997811
Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes
NCT04997811, Phase 2, Unknown, Prof. Janet Dunn
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes. Trials, record NCT04997811. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04997811
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes
- NCT number
- NCT04997811
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Prof. Janet Dunn
- Conditions
- Myelodysplastic Syndromes (MDS)
- Interventions
- Sodium Valproate, Bezafibrate, Medroxyprogesterone, Danazol
- First posted
- 2021-08-10
- Last updated
- 2023-10-03
- Other registries' IDs
- eudract:2020-005446-42
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Haematological improvement (HI) in each arm and in the trial overall, with 25% or more of the participants having HI in each arm and overall. | 12 months | HI will be assessed in each participant by comparing post randomisation FBC parameters (Haemoglobin, platelet and neutrophil counts) and transfusion requirements, with their individual baseline as determined by the IWG 2018 haematology response criteria in patients with MDS. |
| Secondary | Reduced burden of red cell and/or platelet transfusion in each arm and in the trial overall, as per the IWG 2018 response criteria. | 12 months | Changes in transfusion requirements will be assessed in each participant by comparison with their individual 16-week lead-in baseline as determined by the IWG 2018 haematology response criteria in patients with MDS. |
| Secondary | Duration of haematological response | 12 months | Clinically meaningful haematological responses that persist for 16 weeks or longer. |
| Secondary | Reported improved Health Related Quality of Life scores in each arm and in the trial overall. | 12 months | The four Health Related Quality of Life questions measure 1) self-perceived health (excellent, very good, good, fair, or poor), (2) number of days out of the past 30 that physical health was not good, (3) number of days out of the past 30 that mental health was not good, and (4) number of days out of the past 30 that usual activities were limited by poor physical or mental health of life scores will be evaluated using established protocols. |
| Secondary | Overall survival | Through study completion, an average of 1 year | Overall survival at close of trial will be reported separately for each trial arm |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04997811
GET https://conductscience.org/api/trials/v1/NCT04997811/registered